B+
Bull case
15%
Probability
Target price
$0.85
Analysis reference price unavailable
Analysis 2026-05-30 · RankAlpha Sentiment Codex
ENSC
Ensysce BiosciencesFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
If Nasdaq accepts the plan and PF614-301 keeps advancing, the stock can still re-rate sharply because the current equity base is tiny and any clinical de-risking would matter disproportionately.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.0.
What can break
Cash and cash equivalents were only $745,482 at 2026-03-31, versus $4.31 million at 2025 year-end, and management says cash only funds operations into late Q2 2026 [#10-Q-2026-05-15].
Momentum
81
Value
41
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.18 · Bull $0.85 · Bear $0.05Analysis 2026-05-30; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-10 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-30 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-10
Investment thesis
As of 2026-09-10
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-10. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $8.25
Why
Momentum81 · Δ7d -
Value41 · Δ7d -0.0
Sentiment0 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.0.
Contradictions & invalidation
- • Cash and cash equivalents were only $745,482 at 2026-03-31, versus $4.31 million at 2025 year-end, and management says cash only funds operations into late Q2 2026 [#10-Q-2026-05-15].
- • Future viability depends on raising additional capital, which could be materially dilutive [#10-Q-2026-05-15].
- • If the plan is rejected, financing arrives on punitive terms, or clinical progress stalls, dilution and listing risk are likely to dominate price action and keep the equity under pressure.
Catalyst clock
2026-07-06
Nasdaq equity shortfall enters a formal plan window
Lead driver: Value · See fundamentals
Momentum
81
9% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
0
62% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade F. Momentum 81.5 / Value 41.2 / Sentiment 0.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-30. Scenario method
B
Base case
40%
Probability
Target price
$0.18
Analysis reference price unavailable
Analysis 2026-05-30 · RankAlpha Sentiment Codex
Most likely
B-
Bear case
45%
Probability
Target price
$0.05
Analysis reference price unavailable
Analysis 2026-05-30 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$7.33M
Beta
1.18
Shares Out
15.37M
P/E (TTM) · Derived
-0.1
P/S (TTM)
0.82
P/FCF (TTM) · Derived
-0.27
Rev YoY
-15.1%
EPS YoY
-74.9%
Gross Margin
+100.0%
Op Margin
-281.3%
Net Debt
-$4.03M
Current Ratio
0.60
As of 2026-09-10 • Updated nightlySource: Internal modelMethods & Data